Articles On Neurotech International (ASX:NTI)

A quick wrap of the key winners and losers on Wednesday, June 24. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 741 stocks rose, 697 declined and 764 we...

A quick wrap of the key winners and losers on Friday, June 19. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 806 stocks rose, 483 declined and 825 were...

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 134-odd small cap health stocks and of those which were trading on Wednesday, 71 were in positive territory over the last fortnight, 11 were flat and 52 saw...

A quick wrap of the key winners and losers on Tuesday, June 9. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made potentially market-moving announcements during the day.   WINNERS: CODE COMPANY PRI...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Backpackers in Bondi were pilloried for spreading COVID-19, but everyone knows gonorrhoea is a greater risk in the suburb’s sandy stews. Antibiotic maker Recce Pharmaceuticals (ASX: RCE) says its lead candidate is proving to be effective ag...

With the health and life science sector being the ASX’s top performer last year, Western Australia is keen to join the party. The state government has formed an Industry Reference Group to come up with a five-year growth plan for the indust...

The ASX had its worst day of the year so far as it woke up from Australia Day weekend to find global markets retreating on the back of renewed coronavirus fears. The benchmark ASX 200 index shaved off more than a week’s worth of gains a...

Autism treatment company Neurotech International (NTI) has had its flagship device cancelled from the Australian Registry of Therapeutic Goods The device, called Mente Autism, was cancelled after failing a review by the Therapeutic Goods...

Antisense Therapeutics (ASX:ANP) jumped over 20 per cent this morning on news its ATL1102 drug, fighting Duchenne Muscular Dystrophy (DMD), delivered strong preliminary results in its clinical trial. The stock is now up 270 per cent over th...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

In 2019, 10 stocks have gained more than 200 per cent in a single day. Stockhead recaps these stocks, why they gained and where they are now.   10. AssetOwl (ASX: AO1) +225% (16 April) A fellow micro-cap gave AssetOwl a massive leg up back...

At Stockhead we are as amazed as our readers when stocks rise by over 100 per cent in a day. But its a more common occurrence than we thought. There have been 23 stocks that have achieved that feat. The three most common reasons are success...

Leading medical device company Neurotech International (ASX:NTI) this week reported highly promising results from US clinical trials of its Mente autism device.